Business Wire

CorMatrix Names Andrew M. Green President and Chief Operating Officer

ROSWELL, Ga.--(BUSINESS WIRE)--CorMatrix ® Cardiovascular, Inc. a leading developer of biomaterial compositions and medical devices for regenerative medicine, announced effective January 1, 2016 it ...
Business Insider

CorMatrix® Cardiovascular, Inc. receives FDA IDE approval to conduct the safety and feasibility clinical trial of the Cor™ TRICUSPID ECM® valve for pediatric and adult patients

ATLANTA, Jan. 24, 2019 /PRNewswire/ -- CorMatrix ® Cardiovascular, Inc. www.cormatrix.com, a leading developer of regenerative cardiovascular medical devices, today announced FDA approval of an early ...
TCTMD

CorMatrix® CanGaroo® ECM® Envelope Receives CE Mark Approval

ROSWELL, Ga.CorMatrix® Cardiovascular Incorporated, a company specializing in its extracellular matrix (ECM®) technology announced today that it has received CE mark approval for its CorMatrix® ...
TCTMD

CorMatrix® Cardiovascular, Inc. Treats First Patient in Its US Clinical Study for CorMatrix® ECM® Tricuspid Valve at Franciscan St. Francis Health Indianapolis, IN

ROSWELL, Ga., CorMatrix Cardiovascular, Inc., a leading developer of biomaterials and medical devices, today announced treatment of the first patient to receive their tissue engineered regenerative ...
Medindia

CorMatrix Announces Pre-Clinical Data Suggesting Next Generation ECM Technology(TM) Can Improve Cardiac Function

NEW ORLEANS, Nov. 10 CorMatrix Cardiovascular, Inc., anAtlanta-based company dedicated to developing and delivering uniqueextracellular matrix (ECM(TM)) biomaterial devices that harness the ...
Business Insider

CorMatrix® Cardiovascular, Inc. Receives European Community and U.S. Patent Claim Allowances for Polymer Drug Delivery Prostheses

ATLANTA, Aug. 5, 2020 /PRNewswire/ -- CorMatrix ® Cardiovascular, Inc., (www.cormatrix.com) a leading developer of regenerative biomaterial compositions and medical devices, today announced European ...
Seeking Alpha

Ligand Pharma acquires multiple programs from CorMatrix for $17.5M

Ligand Pharmaceuticals (NASDAQ:LGND) purchases the economic rights to multiple programs from privately-held CorMatrix for $17.5M. The deal includes synthetic royalties from sales of CorMatrix's ...